FVADT方案治疗多发性骨髓瘤临床疗效观察被引量：1

下载PDF

导出

摘要目的观察FVADT方案(氟达拉滨、长春新碱、表阿霉素、地塞米松、沙立度胺)治疗多发性骨髓瘤(multiple myeloma,MM)的疗效和不良反应,以期为MM患者探索安全有效的治疗方法。方法回顾性分析接受FVADT方案的MM患者(FVADT组)22例,观察其部分缓解(PR)率、达到PR时间、无进展生存期(PFS)及总生存期(OS),并与33例接受VAD(长春新碱、表阿霉素、地塞米松)方案的患者(VAD组)相比较,并记录化疗相关不良反应。结果 FVADT组的PR率明显高于VAD组(P<0.05),而两组达到PR的时间差异无显著性(P>0.05)。FVADT组的PFS及OS均较VAD组明显延长(P<0.05)。FVADT组WBC下降的最低值低于VAD组,而且WBC上升至1.5×109.L-1的时间也比VAD组延长。FVADT组治疗过程中出现便秘、腹胀、嗜睡、发热等不良反应概率高于VAD组。结论 FVADT方案治疗MM患者PR率明显高于VAD方案,且PFS及OS均较VAD方案明显延长,虽然FVADT方案对骨髓的抑制较VAD方案显著,但可控制。总体而言,FVADT是一种治疗MM安全、疗效更佳的方案。

作者董维蔡嘉惠杨辉翟晓

机构地区广东省佛山市顺德第一人民医院血液肿瘤科

出处《广东医学》 CAS CSCD 北大核心 2011年第13期1746-1748,共3页 Guangdong Medical Journal

基金广东省佛山市医学科技攻关项目(编号:200708139)

关键词多发性骨髓瘤化疗氟达拉滨沙立度胺

分类号 R733.3 [医药卫生—肿瘤]

引文网络
相关文献

参考文献9

1KEATING M J, KANTARJIAN H, TALPAZ M, et al. nudara- blue: A new agent witll major activity against chronic lymphocytic leukemia[J]. Blood, 1989, 74(1): 19-25.
2BJORKSTRAND B, RASMUSSEN T, REMES K, et al. Feasibili- ty of fludarabine added to VAD during induction therapy in multi- ple myeloma : a randomized phase pilot Ⅱ - study [ J ]. Eur J Haematol. 2003. 70(6) : 379-383.
3BLADE J, SAMSON D, REECE D. Criteria for evaluating disease re- sponse and progression in patients with mtdtiple myeloma treated by high -dose therapy and haemopoietie stem cell transplantation. Mye- loma Subcommittee of the EBMT. European Group for Blood and Marrow Transplant[J]. Br J Haematol, 1998, 102(5): 1115-1123.
4罗绍凯,李娟,洪文德,赵莹,童秀珍.FND方案治疗难治性、复发性多发性骨髓瘤的初步报告[J].癌症,2005,24(12):1518-1521. 被引量：14
5彭志刚,周亚丽,黄潇,罗军,赖永榕.氟达拉滨对多发性骨髓瘤细胞系KM3细胞分泌IL-6的影响[J].肿瘤,2007,27(2):147-149. 被引量：3
6RAJKUMAR S V, KYLE R A. Anginogenesis in multiple myeloma [J]. Semin Oncol, 2001, 28(6) : 560 -564.
7KNELLER A, RAANANI P, HARDAN 1, et al. Therapy with thanlidomide in refractory multiple myeloma patients the revival of an old drug[J]. Br J Haematol, 2000, 108(2) : 391 -393.
8BARLOGIE B, ZANGAR1 M, SPENCER T, et al. Thanlidomide in the management of multiple myeloma [ J ]. Semin Hematol, 2001, 38(3) : 250 -259.
9SAHEBI F, SPIELBERGER R, KOGUT N M, et al. Maintenance thalidomide following single cycle autologous peripheral blood stem cell transplant in patients with multiple myeloma [ J ]. Bone Mar- row Transplant, 2006, 37 (9) : 825 - 829.

二级参考文献12

1王学文,杨天楹.难治性和复发性骨髓瘤的治疗进展[J].国外医学（输血及血液学分册）,1993,16(1):35-37. 被引量：11
2侯健,孔宪涛,张和君.IL-6、IL-1及TNF对人类骨髓瘤细胞系KM_2、KM_3增殖的影响[J].中国免疫学杂志,1993,9(1):27-30. 被引量：10
3罗绍凯,李娟,洪文德,赵莹,童秀珍.FND方案治疗难治性、复发性多发性骨髓瘤的初步报告[J].癌症,2005,24(12):1518-1521. 被引量：14
4Klasa R J, Meyer RM, Shustik C, et al. Randomized phase Ⅲ study of fludarabine phosphate versus cyclophosphamide,vincristine, and prednisone in patients with recurrent low-grade non-Hodgkin's lymphoma previously treated with an alkylating agent or alkylator-containing regimen [J]. J Clin Oncol, 2002,20 (24): 4649-4654.
5Bjorkstrand B, Rasmussen T, Remes K, et al. Feasibility of fludarabine added to VAD during induction therapy in multiple myeloma: a randomized phase Ⅱ study [J]. Eur J Haematol,2003,70(6): 379-383.
6Durie BG, Salmon SE. A clinical staging system for multiple myeloma correlation of measured myeloma cell mess with presenting clinical features response to treatment and survival[J]. Cancer, 1975,36(3):842-854.
7Giles FJ. Refractory multiple myeloma:recent advances in therapy [J]. Hematol Pathol, 1995,9(3-4): 121-140.
8KEATING MJ,KANTARJIAN H,TALPAZ M,et al.Fludarabine:A new agent with major activity against chronic lymphocytic leukemia[J].Blood,1989,74(1):19-25.
9BJORKSTRAND B,RASMUSSEN T,REMES K,et al.Feasibility of fludarabine added to VAD during induction therapy in multiple myeloma:a randomized phase pilot Ⅱ-study[J].Eur J haematol,2003,76(6):379-383.
10KRETT NL,AYRES M,MA C,et al.In vitro assessment of nucleoside analogs in multiple myeloma[J].Cancer Chemother Pharmacol,2004,54(2):113-121.